AVALO THERAPEUTICS, INC.: operating lease right-of-use asset

What this measure means

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Exact concept: us-gaap:OperatingLeaseRightOfUseAsset. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2019-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.

Selected filing history

Related financial histories

• AVALO THERAPEUTICS, INC.: total assets
• AVALO THERAPEUTICS, INC.: total liabilities
• AVALO THERAPEUTICS, INC.: stockholders equity
• AVALO THERAPEUTICS, INC.: cash and cash equivalents
• AVALO THERAPEUTICS, INC.: net income or loss
• AVALO THERAPEUTICS, INC.: operating cash flow
• AVALO THERAPEUTICS, INC.: capital expenditure payments
• AVALO THERAPEUTICS, INC.: revenue
• AVALO THERAPEUTICS, INC.: contract revenue excluding tax
• AVALO THERAPEUTICS, INC.: financing cash flow
• AVALO THERAPEUTICS, INC.: investing cash flow
• AVALO THERAPEUTICS, INC.: retained earnings or deficit
• AVALO THERAPEUTICS, INC.: basic weighted-average shares
• AVALO THERAPEUTICS, INC.: diluted weighted-average shares
• AVALO THERAPEUTICS, INC.: basic earnings per share
• AVALO THERAPEUTICS, INC.: diluted earnings per share
• AVALO THERAPEUTICS, INC.: income tax expense or benefit
• AVALO THERAPEUTICS, INC.: net property, plant and equipment
• AVALO THERAPEUTICS, INC.: share-based compensation expense
• AVALO THERAPEUTICS, INC.: operating income or loss
• AVALO THERAPEUTICS, INC.: current assets
• AVALO THERAPEUTICS, INC.: current liabilities
• AVALO THERAPEUTICS, INC.: current accounts payable
• AVALO THERAPEUTICS, INC.: goodwill carrying amount
• AVALO THERAPEUTICS, INC.: net finite-lived intangible assets
• AVALO THERAPEUTICS, INC.: operating expenses
• AVALO THERAPEUTICS, INC.: net inventory
• AVALO THERAPEUTICS, INC.: research and development expense
• AVALO THERAPEUTICS, INC.: common shares outstanding
• AVALO THERAPEUTICS, INC.: cash including restricted cash
• AVALO THERAPEUTICS, INC.: additional paid-in capital
• AVALO THERAPEUTICS, INC.: operating lease liability
• AVALO THERAPEUTICS, INC.: gross property, plant and equipment
• AVALO THERAPEUTICS, INC.: accumulated depreciation on property, plant and equipment
• AVALO THERAPEUTICS, INC.: net intangible assets excluding goodwill
• AVALO THERAPEUTICS, INC.: other noncurrent liabilities
• AVALO THERAPEUTICS, INC.: prepaid expenses and other current assets
• AVALO THERAPEUTICS, INC.: net deferred tax assets
• AVALO THERAPEUTICS, INC.: net deferred tax liabilities
• AVALO THERAPEUTICS, INC.: pre-tax income or loss from continuing operations
• AVALO THERAPEUTICS, INC.: net income available to common stockholders
• AVALO THERAPEUTICS, INC.: general and administrative expense
• AVALO THERAPEUTICS, INC.: depreciation expense
• AVALO THERAPEUTICS, INC.: depreciation, depletion and amortization
• AVALO THERAPEUTICS, INC.: amortization of intangible assets
• AVALO THERAPEUTICS, INC.: other nonoperating income or expense
• AVALO THERAPEUTICS, INC.: nonoperating income or expense
• AVALO THERAPEUTICS, INC.: current income tax expense or benefit
• AVALO THERAPEUTICS, INC.: deferred income tax expense or benefit
• AVALO THERAPEUTICS, INC.: interest paid, net
• AVALO THERAPEUTICS, INC.: proceeds from issuing common stock
• AVALO THERAPEUTICS, INC.: change in accounts receivable
• AVALO THERAPEUTICS, INC.: change in inventories
• AVALO THERAPEUTICS, INC.: change in accounts payable

Inspect the source

Entity

AVALO THERAPEUTICS, INC. / CIK 0001534120

Captured

2026-09-20T09:16:35.394Z

SEC response SHA-256

c27cef5388033067af62e0489a1b2af90f086713b680df0f63e0f63ad2ea1ca3

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001534120.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))